MedTrace Logo

Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache

NCT00311662 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2009-08-31

No results posted yet for this study

Summary

Overall trial objectives:

* Can treatment with tonabersat reduce the number of days with a migraine headache in patients who suffer from frequent migraine attacks
* How well tolerated is treatment with tonabersat

The study is based on the hypothesis that the unique mechanism of action of tonabersat will inhibit some of the early events in the generation of migraine and so be effective as prophylactic treatment

Conditions

  • Migraine Without Aura
  • Migraine With Aura

Interventions

DRUG

Tonabersat

Tablet 40mg daily for 12 weeks

DRUG

Placebo

Tablet once daily for 12 weeks

Sponsors & Collaborators

  • Minster Research Ltd

    lead INDUSTRY

Principal Investigators

  • Peter Goadsby, MD · The National Hospital for Neurology and Neurosurgery, London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-10-31
Completion
2006-10-31

Countries

  • Denmark
  • Hungary
  • South Africa
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00311662 on ClinicalTrials.gov